PI3K/Akt-mediated regulation of p53 in cancer

Biochemical Society Transactions

Volumn 42, Issue 4, 2014, Pages 798-803

  Abraham, Aswin G ^a   O'Neill, Eric ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Acquired resistance; Akt; Alternative reading frame (ARF); Murine double minute 2 (MDM2); Phosphoinositide 3 kinase (PI3K); TP53

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN MDM2; PROTEIN P53; RAS PROTEIN; ENZYME INHIBITOR; MDM2 PROTEIN, HUMAN;

BREAST CANCER; CELL DEATH; CONFERENCE PAPER; DNA DAMAGE; HUMAN; MISSENSE MUTATION; NEOPLASM; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REGULATORY MECHANISM; SENESCENCE; URINARY TRACT CANCER; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; METABOLISM; NEOPLASMS; SIGNAL TRANSDUCTION;

ENZYME INHIBITORS; HUMANS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84905867778     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20140070     Document Type: Conference Paper

References (84)

1. Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674
2. Atlas, T.C.G. (2012) Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70
3. Brosh, R. and Rotter, V. (2009) When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer 9, 701-713
4. Freed-Pastor, W.A. and Prives, C. (2012) Mutant p53: one name, many proteins. Genes Dev. 26, 1268-1286
5. Hanel, W., Marchenko, N., Xu, S., Yu, S.X., Weng, W. and Moll, U. (2013) Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ. 20, 898-909
6. Muller, P.A., Caswell, P.T., Doyle, B., Iwanicki, M.P., Tan, E.H., Karim, S., Lukashchuk, N., Gillespie, D.A., Ludwig, R.L., Gosselin, P. et al. (2009) Mutant p53 drives invasion by promoting integrin recycling. Cell 139, 1327-1341
7. Nogueira, V., Park, Y., Chen, C.C., Xu, P.Z., Chen, M.L., Tonic, I., Unterman, T. and Hay, N. (2008) Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 14, 458-470
8. Mayo, L.D. and Donner, D.B. (2001) A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. U.S.A. 98, 11598-11603
9. Hennessy, B.T., Smith, D.L., Ram, P.T., Lu, Y. and Mills, G.B. (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4, 988-1004
10. Fruman, D.A., Meyers, R.E. and Cantley, L.C. (1998) Phosphoinositide kinases. Annu. Rev. Biochem. 67, 481-507
11. Song, M.S., Salmena, L. and Pandolfi, P.P. (2012) The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 13, 283-296
12. Osaki, M., Oshimura, M. and Ito, H. (2004) PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9, 667-676
13. Hafsi, S., Pezzino, F.M., Candido, S., Ligresti, G., Spandidos, D.A., Soua, Z., McCubrey, J.A., Travali, S. and Libra, M. (2012) Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). Int. J. Oncol. 40, 639-644
14. Haupt, S., Berger, M., Goldberg, Z. and Haupt, Y. (2003) Apoptosis: the p53 network. J. Cell Sci. 116, 4077-4085
15. Riley, T., Sontag, E., Chen, P. and Levine, A. (2008) Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 9, 402-412
16. Hemann, M.T. and Lowe, S.W. (2006) The p53-Bcl-2 connection. Cell Death Differ. 13, 1256-1259
17. Wade, M., Li, Y.C. and Wahl, G.M. (2013) MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer 13, 83-96
18. Sherr, C.J. (2006) Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer 6, 663-673
19. Christophorou, M.A., Ringshausen, I., Finch, A.J., Swigart, L.B. and Evan, G.I. (2006) The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443, 214-217
20. Efeyan, A., Garcia-Cao, I., Herranz, D., Velasco-Miguel, S. and Serrano, M. (2006) Tumour biology: policing of oncogene activity by p53. Nature 443, 159
21. Kamijo, T., Zindy, F., Roussel, M.F., Quelle, D.E., Downing, J.R., Ashmun, R.A., Grosveld, G. and Sherr, C.J. (1997) Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91, 649-659
22. Sharpless, N.E. (2005) INK4a/ARF: a multifunctional tumor suppressor locus. Mutat. Res. 576, 22-38
23. Vousden, K.H. and Prives, C. (2009) Blinded by the light: the growing complexity of p53. Cell 137, 413-431
24. Suh, Y.A., Post, S.M., Elizondo-Fraire, A.C., Maccio, D.R., Jackson, J.G., El-Naggar, A.K., Van Pelt, C., Terzian, T. and Lozano, G. (2011) Multiple stress signals activate mutant p53 in vivo. Cancer Res. 71, 7168-7175
25. Haupt, S., Mitchell, C., Corneille, V., Shortt, J., Fox, S., Pandolfi, P.P., Castillo-Martin, M., Bonal, D.M., Cordon-Cardo, C., Lozano, G. and Haupt, Y. (2013) Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. Cell Cycle 12, 1722-1731
26. Terzian, T., Suh, Y.A., Iwakuma, T., Post, S.M., Neumann, M., Lang, G.A., Van Pelt, C.S. and Lozano, G. (2008) The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev. 22, 1337-1344
27. Lang, G.A., Iwakuma, T., Suh, Y.A., Liu, G., Rao, V.A., Parant, J.M., Valentin-Vega, Y.A., Terzian, T., Caldwell, L.C., Strong, L.C. et al. (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119, 861-872
28. Olive, K.P., Tuveson, D.A., Ruhe, Z.C., Yin, B., Willis, N.A., Bronson, R.T., Crowley, D. and Jacks, T. (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847-860
29. Adams, J.R., Schachter, N.F., Liu, J.C., Zacksenhaus, E. and Egan, S.E. (2011) Elevated PI3K signaling drives multiple breast cancer subtypes. Oncotarget 2, 435-447
30. Mao, L., Merlo, A., Bedi, G., Shapiro, G.I., Edwards, C.D., Rollins, B.J. and Sidransky, D. (1995) A novel p16INK4A transcript. Cancer Res. 55, 2995-2997
31. Duro, D., Bernard, O., Della Valle, V., Berger, R. and Larsen, C.J. (1995) A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies. Oncogene 11, 21-29
32. Chen, D., Shan, J., Zhu, W.G., Qin, J. and Gu, W. (2010) Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses. Nature 464, 624-627
33. Burd, C.E., Jeck, W.R., Liu, Y., Sanoff, H.K., Wang, Z. and Sharpless, N.E. (2010) Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk. PLoS Genet. 6, e1001233
34. Gonzalez, S., Klatt, P., Delgado, S., Conde, E., Lopez-Rios, F., Sanchez-Cespedes, M., Mendez, J., Antequera, F. and Serrano, M. (2006) Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. Nature 440, 702-706
35. Maeda, T., Hobbs, R.M., Merghoub, T., Guernah, I., Zelent, A., Cordon-Cardo, C., Teruya-Feldstein, J. and Pandolfi, P.P. (2005) Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature 433, 278-285
36. Enomoto, T., Lindstrom, M.S., Jin, A., Ke, H. and Zhang, Y. (2006) Essential role of the B23/NPM core domain in regulating ARF binding and B23 stability. J. Biol. Chem. 281, 18463-18472
37. Gjerset, R.A. (2006) DNA damage, p14ARF, nucleophosmin (NPM/B23), and cancer. J. Mol. Histol. 37, 239-251
38. Itahana, K., Bhat, K.P., Jin, A., Itahana, Y., Hawke, D., Kobayashi, R. and Zhang, Y. (2003) Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol. Cell 12, 1151-1164
39. Korgaonkar, C., Hagen, J., Tompkins, V., Frazier, A.A., Allamargot, C., Quelle, F.W. and Quelle, D.E. (2005) Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol. Cell. Biol. 25, 1258-1271
40. Kuo, M.L., den Besten, W., Bertwistle, D., Roussel, M.F. and Sherr, C.J. (2004) N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev. 18, 1862-1874
41. Goh, A.M., Coffill, C.R. and Lane, D.P. (2011) The role of mutant p53 in human cancer. J. Pathol. 223, 116-126
42. Bergamaschi, D., Gasco, M., Hiller, L., Sullivan, A., Syed, N., Trigiante, G., Yulug, I., Merlano, M., Numico, G., Comino, A. et al. (2003) p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3, 387-402
43. Di Como, C.J., Gaiddon, C. and Prives, C. (1999) p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell. Biol. 19, 1438-1449
44. Bruno, T., Desantis, A., Bossi, G., Di Agostino, S., Sorino, C., De Nicola, F., Iezzi, S., Franchitto, A., Benassi, B., Galanti, S. et al. (2010) Che-1 promotes tumor cell survival by sustaining mutant p53 transcription and inhibiting DNA damage response activation. Cancer Cell 18, 122-134
45. Zhao, Z.J., Liu, F.Y., Li, P., Ding, X., Zong, Z.H. and Sun, C.F. (2011) CCL19-induced chemokine receptor 7 activates the phosphoinositide-3 kinase-mediated invasive pathway through Cdc42 in metastatic squamous cell carcinoma of the head and neck. Oncol. Rep. 25, 729-737
46. Zhang, X., Tang, N., Hadden, T.J. and Rishi, A.K. (2011) Akt, FoxO and regulation of apoptosis. Biochim. Biophys. Acta 1813, 1978-1986
47. Datta, S.R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y. and Greenberg, M.E. (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231-241
48. Cross, D.A., Alessi, D.R., Cohen, P., Andjelkovich, M. and Hemmings, B.A. (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789
49. Neshat, M.S., Mellinghoff, I.K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J.J., Wu, H. and Sawyers, C.L. (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. U.S.A. 98, 10314-10319
50. Cizkova, M., Dujaric, M.E., Lehmann-Che, J., Scott, V., Tembo, O., Asselain, B., Pierga, J.Y., Marty, M., de Cremoux, P., Spyratos, F. and Bieche, I. (2013) Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab. Br. J. Cancer 108, 1807-1809
51. Muller, P.A., Vousden, K.H. and Norman, J.C. (2011) p53 and its mutants in tumor cell migration and invasion. J. Cell Biol. 192, 209-218
52. Ogawara, Y., Kishishita, S., Obata, T., Isazawa, Y., Suzuki, T., Tanaka, K., Masuyama, N. and Gotoh, Y. (2002) Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J. Biol. Chem. 277, 21843-21850
53. Zhou, B.P., Liao, Y., Xia, W., Zou, Y., Spohn, B. and Hung, M.C. (2001) HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 3, 973-982
54. Gottlieb, T.M., Leal, J.F., Seger, R., Taya, Y. and Oren, M. (2002) Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene 21, 1299-1303
55. Ashcroft, M., Ludwig, R.L., Woods, D.B., Copeland, T.D., Weber, H.O., MacRae, E.J. and Vousden, K.H. (2002) Phosphorylation of HDM2 by Akt. Oncogene 21, 1955-1962
56. Toulany, M., Baumann, M. and Rodemann, H.P. (2007) Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity. Mol. Cancer Res. 5, 863-872
57. Zheng, L., Ren, J.Q., Li, H., Kong, Z.L. and Zhu, H.G. (2004) Downregulation of wild-type p53 protein by HER-2/neu mediated PI3K pathway activation in human breast cancer cells: its effect on cell proliferation and implication for therapy. Cell Res. 14, 497-506
58. Fenouille, N., Puissant, A., Tichet, M., Zimniak, G., Abbe, P., Mallavialle, A., Rocchi, S., Ortonne, J.P., Deckert, M., Ballotti, R. and Tartare-Deckert, S. (2011) SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival. Oncogene 30, 4887-4900
59. Chatzinasiou, F., Lill, C.M., Kypreou, K., Stefanaki, I., Nicolaou, V., Spyrou, G., Evangelou, E., Roehr, J.T., Kodela, E., Katsambas, A. et al. (2011) Comprehensive field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma. J. Natl. Cancer Inst. 103, 1227-1235
60. Astle, M.V., Hannan, K.M., Ng, P.Y., Lee, R.S., George, A.J., Hsu, A.K., Haupt, Y., Hannan, R.D. and Pearson, R.B. (2012) AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. Oncogene 31, 1949-1962
61. Stambolic, V., MacPherson, D., Sas, D., Lin, Y., Snow, B., Jang, Y., Benchimol, S. and Mak, T.W. (2001) Regulation of PTEN transcription by p53. Mol. Cell 8, 317-325
62. Li, Y., Guessous, F., Kwon, S., Kumar, M., Ibidapo, O., Fuller, L., Johnson, E., Lal, B., Hussaini, I., Bao, Y. et al. (2008) PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. Cancer Res. 68, 1723-1731
63. Jen, J., Harper, J.W., Bigner, S.H., Bigner, D.D., Papadopoulos, N., Markowitz, S., Willson, J.K., Kinzler, K.W. and Vogelstein, B. (1994) Deletion of p16 and p15 genes in brain tumors. Cancer Res. 54, 6353-6358
64. Feng, Z. (2010) p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment. Cold Spring Harb. Perspect. Biol. 2, a001057
65. Levine, A.J., Feng, Z., Mak, T.W., You, H. and Jin, S. (2006) Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev. 20, 267-275
66. Blanco-Aparicio, C., Canamero, M., Cecilia, Y., Pequeno, B., Renner, O., Ferrer, I. and Carnero, A. (2010) Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models. PLoS ONE 5, e9305
67. Pires, M.M., Hopkins, B.D., Saal, L.H. and Parsons, R.E. (2013) Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells. Cancer Biol. Ther. 14, 246-253
68. Dong, P., Xu, Z., Jia, N., Li, D. and Feng, Y. (2009) Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway. Mol. Cancer 8, 103
69. Gordon, V. and Banerji, S. (2013) Molecular pathways: PI3K pathway targets in triple-negative breast cancers. Clin. Cancer Res. 19, 3738-3744
70. Olivier, M., Langerod, A., Carrieri, P., Bergh, J., Klaar, S., Eyfjord, J., Theillet, C., Rodriguez, C., Lidereau, R., Bieche, I. et al. (2006) The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin. Cancer Res. 12, 1157-1167
71. Kalinsky, K., Jacks, L.M., Heguy, A., Patil, S., Drobnjak, M., Bhanot, U.K., Hedvat, C.V., Traina, T.A., Solit, D., Gerald, W. and Moynahan, M.E. (2009) PIK3CA mutation associates with improved outcome in breast cancer. Clin. Cancer Res. 15, 5049-5059
72. Boyault, S., Drouet, Y., Navarro, C., Bachelot, T., Lasset, C., Treilleux, I., Tabone, E., Puisieux, A. and Wang, Q. (2012) Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Res. Treat. 132, 29-39
73. Duman, B.B., Sahin, B., Acikalin, A., Ergin, M. and Zorludemir, S. (2013) PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer. J. BUON 18, 44-50
74. Mangone, F.R., Bobrovnitchaia, I.G., Salaorni, S., Manuli, E. and Nagai, M.A. (2012) PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients. Clinics (Sao Paulo) 67, 1285-1290
75. Catasus, L., Gallardo, A., Cuatrecasas, M. and Prat, J. (2009) Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod. Pathol. 22, 522-529
76. Nout, R.A., Bosse, T., Creutzberg, C.L., Jürgenliemk-Schulz, I.M., Jobsen, J.J., Lutgens, L.C., van der Steen-Banasik, E.M., van Eijk, R., Ter Haar, N.T. and Smit, V.T. (2012) Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation. Gynecol. Oncol. 126, 466-473
77. Molinolo, A.A., Hewitt, S.M., Amornphimoltham, P., Keelawat, S., Rangdaeng, S., Meneses Garcia, A., Raimondi, A.R., Jufe, R., Itoiz, M., Gao, Y. et al. (2007) Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin. Cancer Res. 13, 4964-4973
78. Shigaki, H., Baba, Y., Watanabe, M., Murata, A., Ishimoto, T., Iwatsuki, M., Iwagami, S., Nosho, K. and Baba, H. (2013) PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma. Clin. Cancer Res. 19, 2451-2459
79. Cordes, I., Kluth, M., Zygis, D., Rink, M., Chun, F., Eichelberg, C., Dahlem, R., Fisch, M., Hoppner, W., Wagner, W. et al. (2013) PTEN deletions are related to disease progression and unfavourable prognosis in early bladder cancer. Histopathology 63, 670-677
80. Ching, C.B. and Hansel, D.E. (2010) Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway. Lab. Invest. 90, 1406-1414
81. Collins, M.A., Bednar, F., Zhang, Y., Brisset, J.C., Galban, S., Galban, C.J., Rakshit, S., Flannagan, K.S., Adsay, N.V. and Pasca di Magliano, M. (2012) Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J. Clin. Invest. 122, 639-653
82. Morton, J.P., Timpson, P., Karim, S.A., Ridgway, R.A., Athineos, D., Doyle, B., Jamieson, N.B., Oien, K.A., Lowy, A.M., Brunton, V.G. et al. (2010) Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc. Natl. Acad. Sci. U.S.A. 107, 246-251
83. Duffy, M.J., Sturgeon, C., Lamerz, R., Haglund, C., Holubec, V.L., Klapdor, R., Nicolini, A., Topolcan, O. and Heinemann, V. (2010) Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann. Oncol. 21, 441-447
84. Rodon, J., Dienstmann, R., Serra, V. and Tabernero, J. (2013) Development of PI3K inhibitors: lessons learned from early clinical trials. Nat. Rev. Clin. Oncol. 10, 143-153